Excitation-Contraction Coupling in Rat Myocardium: Modulation with Verapamil and Calcium

  • Joseph M. Capasso
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 39)


Verapamil (Isoptin, Knoll) (1), a non-nitrate derivative of papaverine is a vasodilator that produces a short-lasting increase in coronary blood flow and decrease in blood pressure (2) and a long- lasting depression of contractile force (3–5). The uncoupling of excitation from contraction in heart muscle by verapamil is thought to result from its Ca-antagonistic properties (3). Data from both electrophysiological (6–9) and radioactive Ca experiments (4,10) indicate that these drugs reduce transmembrane Ca-influx, a process which is an integral step of excitation-contraction coupling in cardiac muscle (11). Inhibition of calcium influx through the sarcolemma has been postulated for the negative inotropic effect of the drug (3,12,13). This electrogenic influx of calcium occurs during depolarization and has been described by Reuter (11) as a slow inward flow of current and is usually thought to be associated with the plateau of the transmembrane action potential.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Haas H, Harfelder G: Alpha isopropyl gamma ((N methyl N homoveratryl) gamma aminopropryl) 3, 4,—di methoxy phenyl acetonitril, eine Substanz mit coronargefasser weiterenden Eigenschafter. Arztneim Forsch 12: 549–563, 1962.Google Scholar
  2. 2.
    Benfey BG, Grieff K, Heeg E: Evaluation of sympathetic beta receptor blockade by recording the rate of ventricular pressure rise in cats. Br J Pharmacol 30: 23–29, 1967.Google Scholar
  3. 3.
    Fleckenstein A: Specific inhibitors and promoters of calcium action in the excitation-contraction coupling of heart muscle and their role in the prevention or production of myocardial lesions. In: Harris P, Opie LH (ed) Calcium and the heart. Academic Press, New York, 1971, p 135–188:Google Scholar
  4. 4.
    Nayler WG, Szeto J: Effect of verapamil on contractility, oxygen utilization and calcium exchangeability in mammalian heart muscle. Cardiovasc Res 6: 120–128, 1972.PubMedCrossRefGoogle Scholar
  5. 5.
    Watanabe AM, Besch HR: Subcellular myocardial effects of verapamil and D600. Comparaison with propranolol. J Pharmacol Exp Ther 191: 241–251, 1974.PubMedGoogle Scholar
  6. 6.
    Kohlhardt M, Bauer B, Krause H, Fleckenstein A: Differentiation of the transmembrane Na and Ca channels in mammalian cardiac fibers by use of specific inhibitors. Pflugers Arch 335: 309–322, 1972.PubMedCrossRefGoogle Scholar
  7. 7.
    Tritthart H, Volkmann R, Weiss R, Fleckenstein A: Calcium mediated action potentials in mammalian myocardium. Naunyn-Schmiedeberg’s Arch Pharmacol 280: 239–252, 1973.PubMedCrossRefGoogle Scholar
  8. 8.
    Cranefield PF, Aronson RS, Wit AL: Effects of verapamil on the normal action potential and on a Ca-dependent slow response of canine Purkinje fibers. Circ Res 34: 2024–213, 1974.Google Scholar
  9. 9.
    Kass RS, Tsien RW: Multiple actions of calcium antagonists on plateau currents in cardiac Purkinje fibers. J Gen Physiol 66: 169–192, 1975.PubMedCrossRefGoogle Scholar
  10. 10.
    Langer GA, Serena SD, Nudd LM: Localization of contractile-dependent Ca: Comparison of Mn and verapamil in cardiac and skeletal muscle. Am J Physiol 229: 1003–1009, 1975.PubMedGoogle Scholar
  11. 11.
    Reuter H: Divalent cations as charge carriers in excitable membranes. Prog Biophys Mol Biol 26: 1–43, 1973.PubMedCrossRefGoogle Scholar
  12. 12.
    Smith HJ, Goldstein RA, Griffith JM, Kent KM, Epstein SE: Regional contractility. Selective depression of ischemic myocardium by verapamil. Circulation 54: 629–635, 1976.PubMedCrossRefGoogle Scholar
  13. 13.
    Anderson KE: Effects of calcium antagonists on excitation- contraction coupling in striated and smooth muscle. Acta Pharmacol Toxicol 43 (1): 5–14, 1978.Google Scholar
  14. 14.
    Capasso JM, Remily RM, Sonnenblick EH: Alterations in mechanical properties of rat papillary muscle during maturation. Am J Physiol 242: H359–H364, 1982.PubMedGoogle Scholar
  15. 15.
    Capasso JM, Strobeck JE, Malhotra M, Scheuer J, Sonnenblick EH: Contractile behavior of rat myocardium after reversal of hypertensive hypertrophy. Am J Physiol 242: H882–H889, 1982.PubMedGoogle Scholar
  16. 16.
    Capasso JM, Aronson RS, Sonnenblick EH: Reversible alterations in excitation-contraction coupling during myocardial hypertrophy in rat papillary muscle. Circ Res 51: 189–195, 1982.PubMedCrossRefGoogle Scholar
  17. 17.
    Capasso JM, Malhotra A, Remily RM, Scheuer J, Sonnenblick EH: Effects of age on mechanical and electrical performance of rat myocardium. Am J Physiol 245: H72–H81, 1983.PubMedGoogle Scholar
  18. 18.
    Whalen WJ: Oxygen availability in muscle. In: Kavaler F, Roberts J, Tanz F (ed) Factors influencing myocardial contractility. Academic Press, New York, 1967, p 395–40.Google Scholar
  19. 19.
    Pool PE, Chandler BM, Sonnenblick EH, Braunwald E: Integrity of energy stores in cat papillary muscle. Effects of temperature and frequency of contraction on high energy phosphate stores. Circ Res 22: 213–219, 1968.PubMedCrossRefGoogle Scholar
  20. 20.
    Snedecor GW, Cochran WG: Statistical Methods. The Iowa State University Press, Ames, Iowa, 1980, p 215–237.Google Scholar
  21. 21.
    Nie NH, Hull CH, Jenkins JG, Steinbrenner K, Bent DH: Statistical Package for the Social Sciences. McGraw-Hill, New York, 1970.Google Scholar
  22. 22.
    Kavaler F: Membrane depolarization as a cause of tension development in mammalian ventricular muscle. Am J Physiol 197: 968–970, 1959.PubMedGoogle Scholar
  23. 23.
    Morad M, Trautwein W: The effect of the duration of the action potential on contraction in the mammalian heart muscle. Pfluegers Arch 299: 66–82, 1968.CrossRefGoogle Scholar
  24. 24.
    Lorell BH, Barry WH: Effects of verapamil on myocardial systolic and diastolic function during caclium overload. Circulation 62 (3): 293, 1980.Google Scholar
  25. 25.
    Aronson RS, Capasso JM: Negative inotropic effect of elevated extracellular calcium in rat myocardium. J Mole Cell Cardiol 12: 1305–1039, 1980.CrossRefGoogle Scholar
  26. 26.
    Rosen MR, Ilvento JP, Gelband H, Merker C: Effects of verapamil on electrophysiological properties of canine Purkije fibers. J Pharmacol Exp Ther 189: 414–42, 1974.PubMedGoogle Scholar
  27. 27.
    Kuroda T: The effects of D6qq and verapamil on action potential in the X-organ neuron of the crayfish. Jap J physiol 26: 189–202,Google Scholar
  28. 28.
    Reuter H: Membrane calcium in ventricular myocardial fibers. J Physiol (Lond) 207: 191–209, 1970.PubMedCentralGoogle Scholar
  29. 29.
    Entman ML, Allen JC, Bornet EP, Gillette PC, Wallick ET, Schwartz A: Mechanism of calcium accumulation and transport in cardiac relaxing system (sarcoplasmic reticulum vesicles): effects of verapamil, D600, X537-A and A23178. J Mole Cell Cardiol 4: 681–687, 1972.CrossRefGoogle Scholar
  30. 30.
    Pang D, Sperelakis N: Calcium antagonistic drugs: uptake into various muscles and effects on Ca++ binding. J Mole Cell Cardiol 15 (4): 15, 1983.Google Scholar
  31. 31.
    Angus JA, Richmond DR, Dhumma-Upakorn P, Cobbin LB, Goodman AH: Cardiovascular action of verapamil in the dog with particular reference to myocardial contracti1ity and atrioventricular conduction. Cardiovasc Res 10: 623–632, 1976.PubMedCrossRefGoogle Scholar
  32. 32.
    Fein FS, Kornstein LB, Strobeck JE, Capasso JM, Sonnenblick: Altered myocardial mechanics in diabetic rats. Circ Res 47: 922–933, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • Joseph M. Capasso

There are no affiliations available

Personalised recommendations